Comparative Pharmacology
Head-to-head clinical analysis: ARISTADA versus SYLEVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTADA versus SYLEVIA.
ARISTADA vs SYLEVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, producing sedation, analgesia, and anxiolysis by reducing norepinephrine release in the locus coeruleus.
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
Adults: 400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Terminal elimination half-life is 27-33 hours in adults with normal renal function. Clinical context: Requires dose adjustment in renal impairment (creatinine clearance <30 mL/min reduces clearance by 50%).
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Renal excretion accounts for approximately 70% of the administered dose as unchanged drug, with biliary/fecal elimination contributing 20-30% (primarily as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic